Abstract: A system for disease prediction includes processing circuitry configured to receive a dataset including data of a pa -tient population, the data including for each of a plurality of patients of the patient population, values for a plurality of features, and a diagnosis value indicating whether a disease has been diagnosed. The processing circuitry is configured to, based on correlations between the values, select from the dataset a plurality of subsets of the features, and, for each of at least one of the subsets, execute a machine learning process with the respective subset and the diagnosis values as input parameters, the execution generating a respective prediction model. The processing circuitry is configured to output the respective prediction model.

Abstract: Various aspects of the subject technology related to systems and methods for predicting sequential organ failure assessment (SOFA) scores using machine learning. A system may be configured to receive patient data including one or more features associated with one or more patients. The system may process the features using one or more SOFA score prediction models derived from at least one machine learning process to output respective predicted SOFA scores. One of the prediction models has been trained to output a first SOFA component score for a first amount of time into the future and a second prediction model has been trained to output a second SOFA component score for the first amount of time into the future. The system may output on a graphical user interface, a total SOFA score, the first SOFA component score, and the second SOFA components score predicted for the respective patient.

Abstract: Described herein are thiolase variants, cells expressing the thiolase variants, and methods of their use for the biosynthesis of desired products.

Abstract: A computer-based method includes receiving health-related data at a computer-based processing system, via a network, wherein the health-related data is associated with each respective one of a plurality of individuals participating in a clinical trial. An artificial intelligence-based evaluation of each of the patients is applied, based on the health-related data, to identify patients for whom participation in the clinical trial should be altered. A notification is generated that, when rendered at a computer-based user interface device, reveals the identified information.

Abstract: The present invention provides novel compounds (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits comprising the inventive compounds, or compositions thereof, for treating and/or preventing a fungal or protozoan infection, inhibiting the activity of a fungal or protozoan enzyme, killing a fungus or protozoon, or inhibiting the growth of a fungus or protozoon. The fungus may be a Candida species, Aspergillus species, or other pathogenic fungal species. The compounds of the invention may inhibit the activity of fungal or protozoan cytochrome b and/or fungal or protozoan Hsp90. The present invention also provides synthetic methods of the inventive compounds.

Abstract: The present invention provides novel compounds (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits comprising the inventive compounds, or compositions thereof, for treating and/or preventing a fungal or protozoan infection, inhibiting the activity of a fungal or protozoan enzyme, killing a fungus or protozoon, or inhibiting the growth of a fungus or protozoon. The fungus may be a Candida species, Aspergillus species, or other pathogenic fungal species. The compounds of the invention may inhibit the activity of fungal or protozoan cytochrome b and/or fungal or protozoan Hsp90. The present invention also provides synthetic methods of the inventive compounds.

Abstract: A computer-based method includes receiving health-related data associated with each respective one of multiple individuals, all of whom have, had, or will likely have the same health-related experience. An algorithm identifies, based on the health-related data, information relevant to facilitate efficient allocation of medical expertise or resources to the health-related experience of one or more of the individuals. A notification is generated that, reveals the identified information. Feedback is received that corresponds to the generated notification, after medical expertise or resources have been allocated in response to the generated notification. The algorithm is then adjusted in view of the feedback received to improve the ability to accurately identify the information relevant to facilitate efficient allocation of medical expertise or resources.

Abstract: Described are novel protease inhibitors and methods for using said protease inhibitors in the treatment of human immunodeficiency virus (HIV) infection.

Abstract: The present invention relates to granulocyte colony stimulating factor (“G-CSF”) analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the present G-CSF analogs. The concept detailed herein involves novel mutants of G-CSF, using single substitutions to amino acids, which were rationally chosen to affect the cellular trafficking of G-CSF and/or G-CSFR. In addition, pharmaceutical compositions, and methods of use are provided.

Abstract: The present invention relates to granulocyte colony stimulating factor (“G-CSF”) analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the present G-CSF analogs. The concept detailed herein involves novel mutants of G-CSF, using single substitutions to amino acids, which were rationally chosen to affect the cellular trafficking of G-CSF and/or G-CSFR. In addition, pharmaceutical compositions, and methods of use are provided.

Abstract: The present invention relates to granulocyte colony stimulating factor (“G-CSF”) analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the present G-CSF analogs. The concept detailed herein involves novel mutants of G-CSF, using single substitutions to amino acids, which were rationally chosen to affect the cellular trafficking of G-CSF and/or G-CSFR. In addition, pharmaceutical compositions, and methods of use are provided.

Abstract: The present invention relates to granulocyte colony stimulating factor (“G-CSF”) analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the present G-CSF analogs. The concept detailed herein involves novel mutants of G-CSF, using single substitutions to amino acids, which were rationally chosen to affect the cellular trafficking of G-CSF and/or G-CSFR. In addition, pharmaceutical compositions, and methods of use are provided.

Abstract: The present computer-implemented process involves a methodology for determining properties of ligands which in turn can be used for designing ligands for binding with protein or other molecular targets, for example, HIV targets. The methodology defines the electrostatic complement for a given target site and geometry. The electrostatic complement may be used with steric complement for the target site to discover ligands through explicit construction and through the design or bias of combinatorial libraries. The definition of an electrostatic complement, i.e., the optimal tradeoff between unfavorable desolvation energy and favorable interactions in the complex, has been discovered to be useful in ligand design. This methodology essentially inverts the design problem by defining the properties of the optimal ligand based on physical principles.